Physician profile
Jan C Weber
NPI 1487637229
$1,819.70
in general payments reported to CMS, 2019-2025
26 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.87 · 2021: $15.47 · 2022: $394 · 2023: $375 · 2024: $489 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.45 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $975.36 | 2022-2025 | Qulipta, Ubrelvy, Duopa |
| E.R. Squibb & Sons, L.L.C. | $211.60 | 2022-2024 | Zeposia |
| Amgen INC. | $99.87 | 2019 | |
| Eisai INC. | $94.23 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $36.38 | 2024 | Ponvory |
| Lilly USA, LLC | $27.86 | 2023-2024 | Mounjaro |
| Sk Life Science, INC. | $24.54 | 2025 | |
| Neurocrine Biosciences, INC. | $24.43 | 2025 | |
| Genentech USA, INC. | $24.03 | 2025 | Ocrevus Zunovo |
| Tg Therapeutics, INC. | $23.96 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $21.91 | 2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $21.56 | 2024 | Nuplazid |
| Genzyme Corporation | $21.06 | 2024 | |
| Tanabe Pharma America, INC. | $21.01 | 2022 | |
| Kyowa Kirin, INC. | $19.62 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.08 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.69 | 2024 | Jardiance |
| Celgene Corporation | $17.69 | 2025 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $17.67 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $17.29 | 2025 | Crexont |
| Merz Pharmaceuticals, LLC | $16.75 | 2025 | Xeomin, Inbrija |
| Mallinckrodt Hospital Products INC. | $15.69 | 2022 | |
| Biogen, INC. | $15.47 | 2021 | |
| Pfizer INC. | $14.44 | 2025 | |
| Novo Nordisk INC | $14.23 | 2023 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $6.28 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.